linjc16/ctgov huggingface dataset:
Cervical Range of Motion in Neck Pain Patients: A Mixed Methods Study

Study Overview
=================
Brief Summary
-----------------
This study there are any associations between objective and subjective outcome measures, measuring the cervical range of motion and if the restriction matter to the patient.

Detailed Description
-----------------
Objective and subjective outcome measures are frequently used assessments in clinical practice. The investigators will use different subjective and objective outcome measures to evaluate any possible associations, as well as to investigate if restrictions of movement matters to patients. Additionally to the assessments tools the investigators will use interviews to extend the scope.

Official Title
-----------------
Cervical Range of Motion in Neck Pain Patients: A Mixed Methods Study

Conditions
-----------------
Neck Pain

Intervention / Treatment
-----------------
* Other: Measurement of the range of motion of the cervical spine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with any duration of neck pain Men and women older than 18 years Signed informed consent Exclusion Criteria: Disc herniation of the cervical spine Spinal canal stenosis Acute accidents Surgery of the cervical spine Pacemaker and / or defibrillator

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Measurement of the range of motion of the cervical spine|There is no intervention. Only measurements and interviews are taken.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cervical Range of Motion (CROM) | The cervical range of motion will be measured using the CROM device | Baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neck Disability Index | Questionnaire, measuring the subjective restriction of the participant during activities of daily living | Baseline | 
| S-ROM-Neck | Questionnaire, the participants will be asked to assess their ability to move there neck and if they feel restricted. | Baseline | 
| Interviews (personal,semi-structured guided, open-ended questions) in a one-to-one Setting. Recorded with a voice-recorder. | 10 of the participants will be asked to also take part in an interview. | Baseline |
Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and efficacy of topical application of IDP-108 versus vehicle in treating patients with onychomycosis.

Conditions
-----------------
Onychomycosis

Intervention / Treatment
-----------------
* Drug: IDP-108
* Drug: Vehicle


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinically diagnosed onychomycosis of the target nail Presence of mild to moderate onychomycosis, defined as 20 - 50% of the area of the target nail being clinically affected Has a positive KOH examination from the target nail Has a positive dermatophyte culture from the target nail Exclusion Criteria: Presence of any disease or condition that might cause nail abnormalities or may interfere with the evaluation of the study drug Use of any systemic antifungal therapy within 4 weeks prior to the Screening visit or non-responsive to systemic antifungal therapy for onychomycosis Use of any prescription or over-the-counter topical antifungal therapy for the toenails within 4 weeks prior to the Screening visit Woman who is pregnant, nursing an infant, or planning a pregnancy during the study period

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: IDP-108<br> | Drug: IDP-108<br>* Topical application once a day for 48 weeks<br>|
| Placebo Comparator: Vehicle<br> | Drug: Vehicle<br>* Topical application once a day for 48 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patients who achieve clinical cure |  | 52 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patients who achieve clinical efficacy |  | 52 weeks | 
| Percentage of patients who achieve mycologic cure |  | 52 weeks |
Taste Supra-thresholds Among a Sample of Depressed Egyptian Adult Under Anti-depressants Therapy

Study Overview
=================
Brief Summary
-----------------
Determine the taste intensity at supra-threshold among a sample of depressed Egyptian adults (age from 20 to 50 years old) under anti-depressants therapy ( for at least 3 months) using filter paper disc(FPD) method using a psychophysical method through a scoring system.

Detailed Description
-----------------
PECO P Population: depressed Egyptian adults under anti-depressants therapy E1 Exposure 1: Tricyclic antidepressants (Imipramine, Amitriptyline, Clomipramine HCL) E2 Exposure 2: Selective Serotonin Re-uptake inhibitors antidepressants ( Fluoxetine, Fluvoxamine, Sertraline, Citalopram, Paroxetine) C control (non exposure) : non-pharmacological treatment ( psychotherapy) O Outcome: Determine the taste intensity at supra-threshold among these patients using a psychophysical method through a scoring system

Official Title
-----------------
Taste Supra-thresholds Among a Sample of Depressed Egyptian Adults Under Anti-depressants Therapy A Retrospective Cohort Study

Conditions
-----------------
Taste Disorders

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Depressed Egyptian adults under antidepressants therapy for at least 3 months/non-pharmacological treatment( psychotherapy) • Age from 20 to 50 years old Exclusion Criteria: Antipsychotics Hypnotics Anticonvulsants Ages other than the mentioned • Olfactory dysfunction Chemosensory dysfunction

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Exposure 1<br>commonly prescribed tricyclic antidepressants (Imipramine, Amitriptyline, Clomipramine HCL) administered for at least 3 months | |
| Exposure 2<br>commonly prescribed Selective Serotonin Re-uptake inhibitors antidepressants ( Fluoxetine, Fluvoxamine, Sertraline, Citalopram, Paroxetine) administered for at least 3 months | |
| Non exposure<br>Non-pharmacological treatment (psychotherapy) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Taste intensity at supra-threshold | - C.M will assess the taste intensity at supra-threshold level on a 9 point vertical labeled scale (extremely strong, very strong, strong, slightly strong, neutral, slightly weak, weak , very weak, extremely weak) in which subjects indicate the intensity perceived when tasting a substance | during a period of 3 months from February 2021 till April 2021] |
Study of the Effects of a Mineralized Water Ingestion Upon Lipidic Absorption Mechanisms

Study Overview
=================
Brief Summary
-----------------
The principal objective of this research is the evaluation of the effect of mineralized water consumption upon evolution of LDL Cholesterol and triglycerides, compared to a low mineralized water consumption.

Official Title
-----------------
Study of the Effects of a Mineralized Water Ingestion Upon Lipidic Absorption Mechanisms

Conditions
-----------------
Moderated Cholesterolemia

Intervention / Treatment
-----------------
* Other: Mineralized water
* Other: Low mineralized water


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI included between 18.5 and 25 kg/m² non smoking moderated hypercholesterolemia Exclusion Criteria: food allergy diabetes high blood pressure kidney deficiency thyroid deficiency metabolism deficiency

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Other: Mineralized water<br> <br> |
| Active Comparator: 2<br> | Other: Low mineralized water<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood LDL Cholesterol rate. |  | Day-1, day-56, day-63, day-119 of study | 
| Post-prandial blood triglycerides rate. |  | Day-1, day-56, day-63, day-119 of the study |
Anesthesia Management of Retroperitoneal Adrenalectomies

Study Overview
=================
Brief Summary
-----------------
This study is a prospective, perioperative evaluation of hemodynamic and respiratory parameters in patients undergoing retroperitoneoscopic adrenalectomies.

Detailed Description
-----------------
Due to their underlying disease, patients with adrenal tumors are prone to episodes of hyper- and hypotension. Furthermore, excessive hypercarbia and an increased arterial-alveolar CO2 difference can be seen during these operations.

Official Title
-----------------
Anesthesiological Management of Hemodynamics and Gas Exchange for Retroperitoneal Adrenalectomies

Conditions
-----------------
Adrenal Tumors

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with an adrenal tumor Exclusion Criteria: Age below 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Pheochromocytoma | |
| 2<br>Conn-Syndrome | |
| 3<br>Cushing disease | |
| 4<br>Metastasis | |
| 5<br>Non-functional tumor | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Arterial-alveolar Carbon dioxide Difference |  | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Perioperative maximal mean arterial pressure |  | 3 Years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
retroperitoneoscopic adrenalectomy, intraoperative arterial-alveolar Carbon dioxide Difference
The Relationship Between Heart Function and Metabolism in HFpEF Patients

Study Overview
=================
Brief Summary
-----------------
HFpEF has gradually become the most common form of heart failure. Studies have found that metabolic abnormalities and chronic inflammation ultimately lead to HFpEF by promoting heart remodeling. However, there are few relevant studies and the mechanism is still unclear.

Detailed Description
-----------------
However, heart failure with preserved ejection fraction is difficult to diagnose and treat due to its unknown pathogenesis and poor prognosis. Ventricular diastolic dysfunction and retention of left ventricular ejection fraction are important pathological features of Heart failure with preserved ejection fraction. Currently, it is widely believed to be a clinical syndrome associated with old age, women, obesity, diabetes, hypertension, atrial fibrillation, coronary heart disease, atherosclerosis, etc. However, the specific mechanism of heart failure with preserved ejection fraction caused by the above-mentioned complications is unknown. In conclusion, the investigators intend to explore the pathogenesis of heart failure with preserved ejection fraction by observing the changes of heart and body metabolism in patients with heart failure with preserved ejection fraction, and provide a basis for the diagnosis and treatment.

Official Title
-----------------
The Relationship Between Heart Function and Metabolism in Heart Failure With Preserved Ejection Fraction Patients

Conditions
-----------------
Heart Failure With Preserved Ejection Fraction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult aged ≥ 18 years old Patients diagnosed with HFpEF; Diagnostic criteria including: LVEF 50% or higher; BNP≥35 pg/mL and/or NTproBNP≥125 pg/mL; Presence of symptoms and/or signs of heart failure; At least one additional criteria: relevant structure heart disease or diastolic dysfunction Exclusion Criteria: Severe liver failure; Other causes of shortness of breath, such as severe pulmonary disease or severe ● chronic obstructive pulmonary disease; Primary pulmonary hypertension. Severe left valvular heart disease. Long-term bedridden or unable to move autonomously Age < 18

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HFpEF<br>Heart failure with preserved ejection fraction | |
| HFrEF<br>Heart failure with reduced ejection fraction | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Muscle mass | The muscle mass of HFpEF patients, such as thigh muscle mass | On admission | 
| Blood uric acid | The blood uric acid of HFpEF patients | On admission | 
| Body fat content | The body fat content of HFpEF patients, such as fat percentage and visceral fat area. | On admission |
Hemodynamic Assessment During Spinal Anesthesia Using Transthoracic Echocardiography'

Study Overview
=================
Brief Summary
-----------------
Rationale: Spinal anesthesia is a safe, frequently used anesthetic technique. The main side effect of spinal anesthesia is hypotension, occuring in up to 85 % of selected cases. This hypotension is often treated with fluid infusion. However, especially in elderly patients, high volume fluid infusion can lead to fluid overload. The effects of spinal anesthesia on preload and fluid responsiveness are not exactly known. Hence, therapy for hypotension after spinal anesthesia might not be adequate. With transthoracic echocardiography, vena cava inferior diameter and collapsibility can be used to monitor fluid responsiveness and guide fluid management. Objective: This study has two main objectives. The first is to explore the effects of spinal anesthesia on hemodynamic parameters of fluid status, especially vena cava inferior diameter and collapsibility. The second goal is to test the interrater variability transthoracic echocardiography exams when performed by (trained) anesthesiologists. Furthermore, the correlation between vena cava inferior collapsibility and the occurence and degree of hypotension (defined as a decrease from baseline of >20% or a systolic pressure < 90 mmHg) after spinal anesthesia will be explored.

Official Title
-----------------
Hemodynamic Assessment During Spinal Anesthesia Using Transthoracic Echocardiography'

Conditions
-----------------
Hypotension, Hypovolemia

Intervention / Treatment
-----------------
* Procedure: transthoracic echocardiography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult age (>18 years) Written informed consent Minor surgery under the umbilicus, e.g. herniorrhaphy, transurethral resection of bladder or prostate, orthopaedic procedures ASA class I or II Exclusion Criteria: No informed consent ASA class III or higher Obstetric surgery Emergency procedures Pre-existing neurological injury or disease Contra-indications for spinal anesthesia (e.g. coagulation abnormalities)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: transthoracic echocardiography|measurement of inferior vena cava diameter during inspiration and expiration using transthoracic echocardiography|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| vena cava inferior collapsibility (in %) | vena cava inferior collapsibility: (Maximum vena cava inferior diameter - Minimum vena cava diameter)/maximum vena cava diameter | 1 hour |
Measurement of Cardiac Output and Intravascular Volume Status in Children Using COstatus (SH)

Study Overview
=================
Brief Summary
-----------------
Assessment and monitoring of cardiac function in the pediatric intensive care unit (PICU) is an integral part of hemodynamic monitoring of critically ill patients whether it is done directly or indirectly. Measurement of cardiac output (CO) can specifically guide therapies to support the cardiovascular system in critically ill children with multi organ dysfunction. Because of the side effects involved in measuring cardiac output directly, intensive monitoring of patients is currently limited to an integrated assessment of tissue perfusion, oxygen delivery and cellular health both at regional and global levels. Currently available methods of measuring CO have their limitations and complications, and are not used routinely for bedside monitoring. Therefore, the investigators propose to use a newly developed method, termed COstatus for the monitoring of CO in patients admitted to PICU.

Official Title
-----------------
Measurement of Cardiac Output and Intravascular Volume Status in Critically Ill Children Using an Ultrasound Dilution Method (COstatus)

Conditions
-----------------
Intensive Care

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients under 21 years Presence of compensated or decompensated shock irrespective of etiology Presence of an existing peripheral arterial and central venous catheters Exclusion Criteria: 1. Patients allergic to heparin

Ages Eligible for Study
-----------------
Maximum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparing CO and other clinical markers in Pediatric ICU | The objective of this study is to see if the CO measurements obtained with COstatus show a linear correlation with all other indirect and invasive methods currently used to measure CO (within acceptable range) and with the CO measured by thermodilution in the cardiac catheterization lab. | During patients stay in ICU with insitu catheter, expected average 3-4 days |
The Effect of Diabetes Mellitus on the Prognosis of Patients With COVID-19

Study Overview
=================
Brief Summary
-----------------
All hospitalised patients with COVID-19 who have positive RT-PCR for SARS-COV-2 will be included in the study. The patients will be divided into two groups, as diabetics and non-diabetics. The COVID-19 patients' medical records will be evaluated and compared in terms of the duration of hospitalization, the presence of lung involvement in Computerised Tomography, the need for intensive care unit and mortality rates in patients with and without diabetes.

Detailed Description
-----------------
All hospitalised patients with COVID-19 who have positive RT-PCR for SARS-COV-2 will be included in the study. The patients will be divided into two groups, as diabetics and non-diabetics. The diagnosis of diabetes mellitus will be extracted from the medical records and medical history of the patients hospitalised with COVID-19. The COVID-19 patients medical records will be evaluated and compared in terms of the duration of hospitalization, the presence of lung involvement in Computerised Tomography, the need for intensive care unit and mortality rates in patients with and without diabetes.

Official Title
-----------------
The Effect of Diabetes Mellitus on the Morbidity and Mortality Rates in Patients With COVID-19

Conditions
-----------------
Covid19, Diabetes Mellitus

Intervention / Treatment
-----------------
* Other: hospitalisation, necessity of ICU, mortality rate, lung involvement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients hospitalized for COVID-19 Exclusion Criteria: Patients with known malignancy Pregnant patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Diabetic groups<br>COVID-19 patients with diabetes mellitus | Other: hospitalisation, necessity of ICU, mortality rate, lung involvement<br>* hospitalisation, necessity of ICU, mortality rate, lung involvement<br>|
| Control groups<br>COVID-19 patients without diabetes mellitus | Other: hospitalisation, necessity of ICU, mortality rate, lung involvement<br>* hospitalisation, necessity of ICU, mortality rate, lung involvement<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of Hospitalisation | The time between admission to hospital and discharge | 1 year | 
| The need for ICU | The admission of hospitalized patients to the intensive care unit. | 1 year | 
| Mortality | Mortality rates of patients | 1 year | 
| Lung involvement | The presence of lung involvement on thorax CT | 1 year |